News

The importance of patient stratification methods based on AI for disease onset and progression prediction

Published on: 02/02/2022

The importance of patient stratification methods based on AI for disease onset and progression prediction
AI

The inherent complexity of degenerative neurological diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and the particular requirement for unravelling new biomarkers warrant a novel approach that integrates biological, clinical, environmental and all other potentially relevant data sources. This heterogeneous data would also be crucial to developing advanced descriptive and predictive models that help medical doctors and enable a more personalized approach. Artificial intelligence (AI), specifically, plays a fundamental role in this step through the time-sensitive analysis of such data sources, including those of genotype-phenotype, clinical temporal, and remote patient monitoring.

The importance of AI-based methods is indeed relevant in discovering significant patterns that are usually too complex to be observed manually or through simple automated approaches. Hence, developing AI-based patient stratification methods is integral to deepening our understanding of patient profiles; improving prognosis of disease progression and its evolution patterns; and providing early-risk prediction tools. In turn, we can achieve personalized treatments through targeted therapies, optimize medical interventions to focus on disease-specific progression rates or avoid unnecessary hospitalizations, and estimate the impact of therapy, i.e., the probability of adverse effects or other complications. In addition, AI-based models could support patient healthcare, providing important predictions about therapies and risk factors.

In this respect, by integrating multiple and heterogeneous data, from clinical to environmental, BRAINTEASER aims to develop AI-based models for patient stratification and disease progression for two challenging degenerative neurological diseases, ALS and MS. It will also aim to develop tools for early-risk prediction of disease progression and adverse events. Through identifying patient profiles and integrating different models and tools, BRAINTEASER will contribute to developing personalized approaches that can lead to better patient prognosis and supportive care.

NEWS​

Related News

New Round Tables announced to drive progress on EHDS and health AI

3 Jul 2025

The European Accessibility Act Is Here. Are You Ready?

2 Jul 2025
Why inclusive design is no longer optional – and how Big Motive can help you lead the way.

DTH-Lab Director: The G7 must act now to address the digital health transformation

2 Jul 2025
As digital platforms increasingly shape health systems and information flows, the G7 must lead in setting global standards to ensure safety, equity an...

InnoHSupport Open Calls

1 Jul 2025
Welcome to the InnoHSupport Open Calls!

Transformative Health Instrument Call 2025

1 Jul 2025
Apply to the Transformative Health Instrument (THI) Call 2025 if you are a growing and innovative healthcare start-up working on solutions that have s...

Longitude Prize on ALS

1 Jul 2025
The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *